Languages Available
 
C

PT. Merck Tbk [MERK]   IDR 5.350  -50 (-0,93%)


Loading...
MERK IDR 5.350  -50 (-0,93%)
Last Update 19 November 2018 04:00 PM
Open
IDR 5.300
Prev Close
IDR 5.400
Offer
IDR 5.350
Bid
IDR 5.300
Day Low
IDR 5.300
Day High
IDR 5.350
Volume
9 Lots (900 Shares)
Transaction Value (IDR)
4,78 M
Frequency
5 (Times)
EPS (IDR)
403,15
PE Ratio (ttm)
13,27 Times
Market Cap. (IDR)
2.396.800,00 M
Market Cap. Rank in Industry
#6 of 11 Companies in Pharmaceuticals
Market Cap. Rank in All Companies
#261 of 638 Companies
F
Net Foreign

This section of IDNFinancials requires you to sign up as a premium member of IDNFinancials.

Please check our pricing page to see all of our features.
O
Overview


PT. Merck Tbk (MERK) is engaged in the pharmaceutical and chemical in Indonesia. In the pharmaceutical field, the company manufacture and sell pharmaceutical renowned brands such as Neurobion ®, Sangobion ® and Glucophage ® with cGMP certified facility; and In chemistry, the company markets a variety of chemicals, dyes, and various other chemical specialties.The commercial production was started in 1974. The company incorporated in the Merck Group, is headquartered in Germany .

I
IPO
IPO Date23 July 1981
Offering Shares1.680.000
Company Listing0
Total List Shares0
Percentage0,00 %
Offering PriceRp 1.900
Fund RaisedRp 3.192.000.000
Securities Administration BureauPT. EDI Indonesia
Lead UnderwriterPT. Bahana Securities, PT. Niaga Securities, PT. Multicor, PT. Ronie Wijata Dharma
Listing BoardDevelopment
No IPO bonds found
No IPO rights issue found
D
Dividend

This section of IDNFinancials requires you to sign up as a premium member of IDNFinancials.

Please check our pricing page to see all of our features.
G
Management
Commissioners
-
President Commissioner
Commissioner
Independent Commissioner
Directors
-
President Director
Director
Director
Director
Graph goes here...
S
Shareholders
No. Shareholder Name Number of Shares Total Paidup Capital Percentage
1. Merck Holding GmbH, Jerman 331.483.000 IDR 16.574.150.000 73,99 %
2. Public (each below 5%) 59.805.080 IDR 2.990.254.000 13,35 %
3. Emedia Export Company mbH, Jerman 56.711.920 IDR 2.835.596.000 12,66 %
V
Videos
IDNFinancials Video - Merck stops chemical business
04 April 2016 01:24 PM
JAKARTA - PT Merck Tbk (MERK) stopped their business segment of chemical imports because it was unrelated with the company’s core business as a pharmaceutical producer regarding the policy of Indonesia’s Trade Department...
IDNFinancials Video - Mercks equity down due to 2015 dividend payout
04 April 2016 10:46 AM
JAKARTA - The equity of PT Merck Tbk (MERK) noted Rp641.64 billion or decreased compared with the same period in 2014 an amounted Rp711.05 billion.   Director of PT Merck Tbk Bambang Nurcahyo stated the company’s equity decreased because the company distributed the dividends twice in 2015...
IDNFinancials Video - National Health Service boosts Mercks Sales Volume
04 April 2016 08:53 AM
JAKARTA – The net sales of PT Merck Tbk (MERK) noted Rp983.44 billion or increased 12% compared with the same period in 2014 an amounted Rp863.20 billion...
S
News Update
29 June 2018 09:40 AM Merck divests its consumer health segment to P&G
A
Announcement
Merck will hold extraordinary shareholders meeting on November 27, 2018
2018-11-05 17:30:00
Links: [1] [2]
Merck distributes cash dividend amounted Rp 260 per share, cum July 2, 2018
2018-06-26 11:40:33
Links: [1] [2]
Merck will hold annual and extraordinary shareholders meeting on June 25, 2018
2018-06-04 13:45:14
Links: [1] [2]
Merck Sharp Dohme Pharma will hold annual shareholders' meeting on June 22, 2017
2017-05-31 11:43:09
Links: [1] [2]
UPDATE: Merck distributes cash dividend Rp 275 per share Cum April 21, 2017
2017-04-21 12:33:36
Links: [1] [2]
S
Financial
Period Revenue Net Profit
Q3 - 2018 314.157 M 48.064 M
Q2 - 2018 294.616 M 38.096 M
Q1 - 2018 311.337 M 52.210 M
Q4 - 2017 258.372 M -6.286 M
Q3 - 2017 291.799 M 50.318 M
Q2 - 2017 290.146 M 34.864 M
Q1 - 2017 316.331 M 65.781 M
Q4 - 2016 227.473 M 28.394 M
Full financial and operational data available to our premium users. Please check our premium data introduction page to learn more about our tools.
No prospectus found